Skip to main
AARD
AARD logo

AARD Stock Forecast & Price Target

AARD Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aardvark Therapeutics Inc. is well-positioned for growth with its lead product candidate, ARD-101, which has entered a Phase 3 clinical trial for treating hyperphagia associated with Prader-Willi Syndrome (PWS), addressing a significant gap in current treatment options. The company's innovative approach of activating Bitter Taste Receptors demonstrates potential for more effective management of hyperphagia, which is a critical need, as existing therapies have been perceived as only mildly effective. Furthermore, projected worldwide sales of $1.5 billion by 2033 indicate strong expectations for market uptake, highlighting the substantial commercial opportunity that ARD-101 could represent in a competitive biopharmaceutical landscape.

Bears say

Aardvark Therapeutics Inc. faces a significant challenge regarding its product candidate ARD-101, which has only been evaluated in a small cohort of 18 PWS subjects; this limited sample raises concerns regarding the generalizability and robustness of its Phase II clinical trial results. Additionally, while the data presented a promising decrease in HQ-CT scores, the findings stem from an open-label study design, which undermines the reliability of the efficacy claims due to potential biases in caregiver reporting. Furthermore, the ongoing hurdles associated with hyperphagia in PWS patients indicate that even if ARD-101 proves to be effective, it must still contend with significant real-world challenges in independent living and caregiver stress.

AARD has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aardvark Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aardvark Therapeutics Inc (AARD) Forecast

Analysts have given AARD a Strong Buy based on their latest research and market trends.

According to 1 analysts, AARD has a Strong Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aardvark Therapeutics Inc (AARD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.